Bisphosphonate complications including osteonecrosis of the jaw.
Bisphosphonate therapy has been incorporated in the standard management of patients with multiple myeloma-related bony disease. Although their efficacy in reducing skeletal related events is important in the supportive management of the myeloma patient, post-marketing experience with this class of agents, particularly the more potent intravenous agents pamidronate and zoledronic acid, have raised cautionary notes regarding the potential side effects of these agents. The focus of this session is to review the risk factors, incidence, prevention strategies and management of bisphosphonate-related osteonecrosis of the jaw. In addition, pathophysiology, incidence and monitoring for renal dysfunction during chronic therapy with these agents are reviewed.
Mehrotra
Bhoomi
B
Long Island Jewish Medical Center, Long Island Campus of the Albert Einstein College of Medicine, 270-05 76th Avenue, New Hyde Park, NY 11040, USA. mehrotra@lij.edu
Ruggiero
Salvatore
S
D050071:Bone Density Conservation Agents / Q000009:adverse effects; D001847:Bone Diseases / Q000150:complications / Q000188:drug therapy; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced*; D007674:Kidney Diseases / Q000209:etiology; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D010020:Osteonecrosis / Q000139:chemically induced*
D050071:Bone Density Conservation Agents; D004164:Diphosphonates